It’s become a familiar dance: A drug company buys a well-established medication developed by another company. It raises the price by an obscene amount. The public reacts with outrage. Congress proclaims the need for inquiries . . . And nothing changes. In a few months, we’re likely to go through all of this again, with another company and another drug—unless Congress tackles the issue with legislation, not just rhetoric, Cleveland Clinic’s Chief Pharmacy Officer Scott Knoer writes in TIME.
Read the entire piece at TIME.com: How to Stop Immoral Drug Price Increases